Autism, Alzheimer disease, and fragile X
APP, FMRP, and mGluR5 are molecular links
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The present review highlights an association between autism, Alzheimer disease (AD), and fragile X syndrome (FXS). We propose a conceptual framework involving the amyloid-β peptide (Aβ), Aβ precursor protein (APP), and fragile X mental retardation protein (FMRP) based on experimental evidence. The anabolic (growth-promoting) effect of the secreted α form of the amyloid-β precursor protein (sAPPα) may contribute to the state of brain overgrowth implicated in autism and FXS. Our previous report demonstrated that higher plasma sAPPα levels associate with more severe symptoms of autism, including aggression. This molecular effect could contribute to intellectual disability due to repression of cell–cell adhesion, promotion of dense, long, thin dendritic spines, and the potential for disorganized brain structure as a result of disrupted neurogenesis and migration. At the molecular level, APP and FMRP are linked via the metabotropic glutamate receptor 5 (mGluR5). Specifically, mGluR5 activation releases FMRP repression of APP mRNA translation and stimulates sAPP secretion. The relatively lower sAPPα level in AD may contribute to AD symptoms that significantly contrast with those of FXS and autism. Low sAPPα and production of insoluble Aβ would favor a degenerative process, with the brain atrophy seen in AD. Treatment with mGluR antagonists may help repress APP mRNA translation and reduce secretion of sAPP in FXS and perhaps autism.
Footnotes
-
Study funding: Supported by the Zenith Award from the Alzheimer's Association and the NIH (AG18379 and AG18884) to D.K.L.
-
- Aβ
- amyloid-β
- AD
- Alzheimer disease
- APP
- Aβ precursor protein
- FMRP
- fragile X mental retardation protein
- FXS
- fragile X syndrome
- FXTAS
- fragile X–associated tremor/ataxia syndrome
- LEARn
- latent early-life associated regulation
- LTD
- long-term depression
- LTP
- long-term potentiation
- mGluR5
- metabotropic glutamate receptor 5
- sAPPα
- secreted α form of the amyloid-β precursor protein
- UTR
- untranslated region
-
Supplemental data at www.neurology.org
-
References e1–e45 are available on the Neurology® Web site at www.neurology.org.
- Received April 14, 2010.
- Accepted December 22, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- APP AND DERIVED METABOLITES
- LINKING sAPP WITH AUTISM
- FEATURES OF AUTISM, AD, AND FXS
- RELATIONSHIPS AMONG NEURONAL PROTEINS IN AUTISM, AD, AND FXS
- ROLE OF GENE–ENVIRONMENT INTERACTION IN THE ETIOLOGY OF NEURODEVELOPMENTAL AND NEURODEGENERATIVE DISORDERS
- SUMMARY, POSSIBLE DRUG TARGETS, AND FUTURE PERSPECTIVES
- DISCLOSURE
- ACKNOWLEDGMENT
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS)J. S. Adams, P. E. Adams, D. Nguyen et al.Neurology, August 27, 2007 -
Clinical Implications of Neuroscience Research
Metabotropic glutamate receptorsSynaptic modulators and therapeutic targets for neurologic diseaseEduardo E. Benarroch et al.Neurology, March 17, 2008 -
Article
ASFMR1 splice variantA predictor of fragile X-associated tremor/ataxia syndromePadmaja Vittal, Shrikant Pandya, Kevin Sharp et al.Neurology: Genetics, July 30, 2018 -
Editorial
Genetics, white matter, and cognitionThe effects of methylation on FMR1Paul A. Nyquist, Randi Hagerman et al.Neurology, May 05, 2017